Effect of antiretroviral combination therapy (zidovudine/didanosine or zidovudine/lamivudine) on quantitative plasma human immunodeficiency virus- ribonucleic acid in children and adolescents infected with human immunodeficiency virus

Journal of Pediatrics

Volumn 130, Issue 2, 1997, Pages 293-299

  Solder, B ^a   Wintergerst, U ^a   Notheis, G ^a   Eberle, J ^a   Gurtler, L ^a   Belohradsky, B H ^a  

^a UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; DIDANOSINE; LAMIVUDINE; VIRUS RNA; ZIDOVUDINE;

ADOLESCENT; ARTICLE; CHILD; CLINICAL ARTICLE; DRUG EFFECT; DRUG MIXTURE; DRUG TOLERABILITY; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MALE; PRIORITY JOURNAL; VIRUS TITRATION;

EID: 0030711058     PISSN: 00223476     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-3476(97)70358-5     Document Type: Article

References (32)

1. S Hammer C Crumpacker R D'Aquila B Jackson J Lathey D. Livnat Use of virologic assays for the detection of human immunodeficiency virus in clinical trials: recommendations of the AIDS Clinical Trials Group Virology Committe J Clin Microbiol 31 1993 2557 2564
2. Concorde Coordinating Committee MRC/ARNS randomized double-blind controlled trial of immediate and deferred zidovudine in symptom-free HIV infection Lancet 343 1994 871 881
3. Italian register for HIV infection in children: features of children perinatally infected with HIV-1 surviving longer than 5 years Lancet 343 1994 191 195
4. SA Fiscus V DeGruttola Ph Gupta DA Katzenstein WA Meyer III ML LoFaro Human immunodeficiency virus type 1 quantitative cell microculture as a measure of antiretroviral efficacy in a multicenter clinical trial J Infect Dis 171 1995 305 311
5. HJ Lin LE Myers B Yen-Lieberman FB Hollinger D Henrard CJ Hooper Multicenter evaluation of quantification methods for plasma human immunodeficiency virus type 1 RNA J Infect Dis 170 1994 553 562
6. C Pachl JA Todd DG Kern PJ Sheridan S-J Fong M Stempien Rapid and precise quantification of HIV-1 RNA in plasma using a branched DNA signal amplification assay J AIDS 8 1995 446 454
7. H Revets D Marissens S Dewit N Clumeck S Lauwers G. Zissis Comparison of three HIV-1 RNA quantification assays: NASBA HIV-1 RNA QT, amplicor HIV monitor and quantiplex HIV RNA assay Proceedings of the molecular approaches to laboratory diagnosis. Feb 18-21, 1995 San Francisco, California
8. C Verhofstede S Reniers F Van Wanzeele J. Plum Evaluation of proviral copy numbers and plasma RNA level as early indi-cators of progression in HIV-1 infection: correlation with viro-logical and immunological markers of disease AIDS 8 1994 1421 1427
9. JW Mellors LA Kingsley CR Rinaldo JA Todd BS Hoo RP Kokka Quantitation of HIV-1 RNA in plasma predicts outcome after seroconversion Ann Intern Med 122 1995 573 579
10. C Loveday A. Hill Prediction of progression to AIDS with serum HIV-1 RNA and CD4 count Lancet 345 1995 790 791
11. S Yerly L Kaiser B Mermillod C Baumberger B Hirschel L. Perrin Response of HIV RNA to didanosine as a predictive marker of survival AIDS 9 1995 159 163
12. MV Ragni DA Amato ML LoFaro the AIDS Clinical Trial Group Randomized study of didanosine monotherapy and combination therapy with zidovudine in hemophilic and nonhemophilic subjects with asymptomatic human immunodeficiency virus-1 infection Blood 85 1995 2337 2346
13. DA Katzenstein M Winters J Bubp D Israelski E Winger TC Merigan Quantitation of human immunodeficiency virus by culture and polymerase chain reaction in response to didanosine after long-term therapy with zidovudine J Infect Dis 169 1994 416 419
14. J-M Molina F Ferchal S Chevret V Barateau C Poirot F Morinet Quantification of HIV-1 virus load under zidovudine therapy in patients with symptomatic HIV infection: relation to disease progression AIDS 8 1994 27 33
15. JJ Eron SL Benoit J Jemsek RD MacArthur J Santana JB Quinn Treatment with lamivudine, zidovudine, or both in HIV-positive patients with 200 to 500 CD4+ cells per cubic millimeter N Engl J Med 333 1995 1662 1669
16. AC Collier RW Coombs MA Fischl PR Skolnik D Northfelt P Boutin Combination therapy with zidovudine and didanosine compared with zidovudine alone in HIV-1 infection Ann Intern Med 119 1993 786 793
17. TC Meng MA Fischl AM Boota SA Spector D Bennett Y Bassiakos Combination therapy with zidovudine and dideoxycytidine in patients with advanced human immunodeficiency virus infection Ann Intern Med 116 1992 13 20
18. S Hammer D Katzenstein M Hughes for the ACTG 175 study team Nucleoside monotherapy vs. combination therapy in HIV infected adults: a randomized, double-blind, placebo-controlled trial in persons with CD4-cell counts 200-500/mm [abstract LB-1]. 35th Interscience Conference on Antimi-crobial Agents and Chemotherapy. San Francisco, California Sept 17-20, 1995
19. P Yeni International Coordinating Committee Preliminary results of the European/Australian Delta trial: based on data up to 31st May, 1995 Fifth European Conference on Clinical Aspects and Treatment of HIV Infection, Copenhagen Sept 26-29, 1995
20. RN Husson BU Mueller M Farley L Woods A Kovacs JC Goldsmith Zidovudine and didanosine combination therapy in children with human immunodeficiency virus infection Pediatrics 93 1994 316 322
21. PM. Rowe Something better than zidovudine for children [letter] Lancet 345 1995 511
22. S Staszewski The European Lamivudine HIV Working group Combination 3TC/ZDV vs. ZDV monotherapy in ZDV experienced HIV-1 positive patients with a CD4 count of 100-400 cells/mm [abstract LB32] Second National Conference on Human Imunodeficiency Retroviruses and Related Infections. Washington, DC Jan 29-Feb 2, 1995
23. L Lewis M Wells S Church S Wheeler S Hall P Pizzo A phase I/II study of 3TC (GR109714X) in children with HIV infection [abstract POB 262059]. Ninth International Conference on AIDS, Berlin June 6-11, 1993
24. R Van Leeuwen C Katlama V Kitchen CAB Boucher R Tubiana M McBride Evaluation of safety and efficacy of 3TC (lamivudine) in patients with asymptomatic or mildly symptomatic human immunodeficiency virus infection: a phase I/II study J Infect Dis 171 1995 1166 1171
25. D Ingrand J Weber CAB Boucher The Lamivudine European HIV Working Group Phase I/II study of 3TC (lamivudine) in HIV-positive, asymptomatic or mild AIDS-related complex patients: sustained reduction in viral markers AIDS 9 1995 1323 1329
26. Working Group on Antiretroviral Therapy: National Pediatric HIV Resource Center Antiretroviral therapy and medical management of the human immunodeficiency virus-infected child Pediatr Infect Dis J 12 1993 513 522
27. Centers for Disease Control 1994 revised classification system for human immunodeficiency virus infection in children less than 13 years of age MMWR Morb Mortal Wkly Rep 43 RR-12 1994 1 10
28. Centers for Disease Control 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults MMWR Morb Mortal Wkly Rep 41 RR-17 1992 1 19
29. OJ Cohen G Pantaleo M Holodniy S Schnittman M Niu C Graziosi Decreased human immunodeficiency virus type 1 plasma viremia during antiretroviral therapy reflects downregulation of viral replication in lymphoid tissue Proc Natl Acad Sci U S A 92 1995 6017 6021
30. WA O'Brien PM Hartigan D Martin the Veterans Affairs Cooperative Study Group on AIDS Changes in plasma HIV-1 RNA and CD4+ lymphocyte counts and the risk of progression to AIDS N Engl J Med 334 1996 426 431
31. PE Palumbo S Kwok S Waters Y Wesley D Lewis McKinney Viral measurement by polymerase chain reaction-based assays in human immunodeficiency virus-infected infants J Pediatr 126 1995 592 595
32. X Wei SK Ghosh ME Taylor VA Johnson EA Emini P Deutsch Viral dynamics in human immunodeficiency virus type 1 infection Nature 373 1995 117 122